-
Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial.Lee CW, Ahn JM, Park SJ et al. -
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trialFeres F, Costa RA, OPTIMIZE Trial Investigators.
-
ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy JACC Guideline Comparison: JACC State-of-the-Art ReviewD Capodanno, F Alfonso, GN Levine et al.
-
Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPTPaolo Z; Liefke C; van der Heijden et al.
-
Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS TrialSS Anand, JW Eikelboom, COMPASS Trial Investigators.
-
P2Y12 Inhibitor Monotherapy with Clopidogrel Versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary InterventionPW Chen, WH Feng, MY Ho et al.
-
Prasugrel versus clopidogrel in patients with acute coronary syndromesWiviott SD, Braunwald E, TRITON-TIMI 38 Investigators.
-
Individualized antiplatelet therapy after drug-eluting stent deployment: Implication of clinical trials of different durations of dual antiplatelet therapyNakamura M, Kougame N, Iijima R et al.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
